Who are Diphtheria Antitoxin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Td alone, Tetanus-diphteria, DTacP-IPV combined vaccine (TETRAXIM™), DT, Td, Tetanus/diphtheria toxoids.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/diphtheria-antitoxin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Diphtheria Antitoxin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diphtheria Antitoxin (Diphtheria Antitoxin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antitoxin (passive immunotherapy). Area: Infectious Disease.

marketed Antitoxin (passive immunotherapy) Diphtheria toxin Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Diphtheria Antitoxin (Diphtheria Antitoxin) — PT Bio Farma. Diphtheria antitoxin is a passive immunotherapy that provides immediate neutralization of diphtheria toxin by binding and inactivating the exotoxin produced by Corynebacterium diphtheriae.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Diphtheria Antitoxin TARGET	Diphtheria Antitoxin	PT Bio Farma	marketed	Antitoxin (passive immunotherapy)	Diphtheria toxin
Td alone	Td alone	Korea University Guro Hospital	marketed	Toxoid vaccine	Tetanus toxin and diphtheria toxin
Tetanus-diphteria	Tetanus-diphteria	Hospital Clinic of Barcelona	marketed	Toxoid vaccine	Tetanus toxin (tetanospasmin) and diphtheria toxin
DTacP-IPV combined vaccine (TETRAXIM™)	DTacP-IPV combined vaccine (TETRAXIM™)	Sanofi	marketed	Combination inactivated vaccine	Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3
DT	DT	Hoffmann-La Roche	marketed	Toxoid vaccine	Diphtheria toxin and tetanus toxin
Td	Td	University of Florida	marketed	Toxoid vaccine	Tetanus toxin (tetanospasmin) and diphtheria toxin
Tetanus/diphtheria toxoids	Tetanus/diphtheria toxoids	London School of Hygiene and Tropical Medicine	phase 3	Toxoid vaccine	Tetanus toxin (tetanospasmin) and diphtheria toxin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antitoxin (passive immunotherapy) class)

PT Bio Farma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diphtheria Antitoxin — Competitive Intelligence Brief. https://druglandscape.com/ci/diphtheria-antitoxin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing